Analysis of the Immunobiology of Acute Myeloid Leukemia Relapses After Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for the Generation of Guidelines and Personalized Therapeutic Pathways

Launched by CICERI FABIO · Nov 16, 2021

Keywords

ClinConnect Summary

This clinical trial is looking at how the immune system affects relapses of Acute Myeloid Leukemia (AML) in patients who have undergone a specific type of treatment called allogeneic hematopoietic stem cell transplantation (HSCT). The goal is to better understand these relapses so that doctors can create personalized treatment plans and guidelines for patients in the future. The study involves collecting samples from patients during their regular check-ups, rather than using new treatments or tests.

To participate, individuals must be adults diagnosed with AML who have experienced a relapse after receiving HSCT, whether from a family member or an unrelated donor. Participants will need to give their consent and must have samples stored in a biobank. Importantly, those currently involved in other clinical trials that don’t allow for additional studies cannot join. Overall, this research aims to improve care for patients facing challenges after their treatment for AML.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patients with Acute Myeloid Leukemia, who relapse after allogeneic transplantation from either family or unrelated donors, regardless of the cellular source of the transplant (bone marrow, mobilized peripheral stem cells or cord blood), who have signed the informed consent of the study;
• • For the coordinating center, all patients who have previously signed informed consent to the "Hematological Neoplasms Biobank" and for which samples, stored in the Biobank are available.
• • For the other centers, all patients who have previously signed an informed consent, aimed at the prior authorization for the storage of samples in the biobank of the aforementioned center, according to centers own practice, and for which samples, stored in a Biobank, are available.
• Exclusion Criteria:
• • Participation in clinical protocols that expressly exclude the possibility of participating in other studies.